Online inquiry

IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14792MR)

This product GTTS-WQ14792MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Multiple myeloma (MM), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14792MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9382MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ1439MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ5028MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ4606MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ6362MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ1309MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ5760MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ10664MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-3819253
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.